激素受体阳性乳腺癌新辅助内分泌治疗时间及对浸润性肿瘤细胞的影响。

IF 3 3区 医学 Q2 ONCOLOGY
Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir
{"title":"激素受体阳性乳腺癌新辅助内分泌治疗时间及对浸润性肿瘤细胞的影响。","authors":"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir","doi":"10.1007/s10549-025-07722-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.\",\"authors\":\"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir\",\"doi\":\"10.1007/s10549-025-07722-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>\",\"PeriodicalId\":9133,\"journal\":{\"name\":\"Breast Cancer Research and Treatment\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10549-025-07722-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07722-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:新辅助化疗已被用于评价肿瘤反应和下期激素敏感的局部乳腺癌。然而,完全的病理反应并不常见。新辅助内分泌疗法(NET)很少用于激素受体(HR)阳性乳腺癌的治疗,通常使用6个月或更短的时间。对NET的反应没有明确的定义,治疗时间也没有明确的参数。方法:回顾性分析在单一机构接受NET治疗至少2个月的hr阳性局部浸润性乳腺癌患者的图表。分析临床特征、药物选择、治疗时间、手术类型、病理特征及残留肿瘤细胞。采用多变量线性回归模型检验NET长度与残留浸润性肿瘤细胞之间的关系。结果:在11年的时间里,104例可评估的hr阳性浸润性乳腺癌患者接受了NET治疗。中位年龄为69岁(范围:31-89岁),88%为绝经后。中位治疗持续时间为8个月,61%的患者至少治疗7个月。与治疗2-6个月的患者(34.9%)相比,接受NET治疗7个月或更长时间的患者的残留细胞量(20.4%)显著降低(p = 0.006)。治疗前和治疗后Ki-67≤10%均伴有较低的残余浸润性肿瘤细胞。残留浸润性细胞与绝经状态或NET药物无关。结论:NET持续时间越长,肿瘤反应越大。在接受7个月或更长时间NET治疗的患者中,平均残余浸润性肿瘤细胞减少42%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.

Purpose: Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.

Methods: A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.

Results: 104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.

Conclusion: Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信